Home Alzheimer’s Disease FDA Approves Cemiplimab as First-Line Treatment for Advanced, High PD-L1 NSCLC

FDA Approves Cemiplimab as First-Line Treatment for Advanced, High PD-L1 NSCLC

The FDA has approved the PD-1 inhibitor cemiplimab-rwlc (Libtayo) as a first-line treatment option for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with 50% or more PD-L1 expression, according to the agent’s developer, Regeneron.1

“The approval of Libtayo to treat first-line advanced non–small cell lung cancer with high PD-L1 expression means physicians and patients have a potent new treatment option against this deadly disease,” Naiyer Rizvi, MD, Price Family Professor of Medicine, Director of Thoracic Oncology and Co-director of Cancer Immunotherapy at Columbia University Irving Medical Center, as well as a steering committee member of the trial, said in press release. “Notably, Libtayo was approved based on a pivotal trial where most [patients receiving chemotherapy] crossed over to Libtayo following disease progression, and that…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments